Tislelizumab Combined With TKI

Phase 2Small molecule

Tislelizumab Combined With TKI is one of 15 small molecule programs targeting Hepatocellular Carcinoma (HCC). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatocellular Carcinoma (HCC)Recruiting

Hepatocellular Carcinoma (HCC)Phase 2

Recruiting

Competition

Competitive Landscape

17 competitors in Hepatocellular Carcinoma (HCC)

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 2

3 2

Yervoy

Bristol-Myers Squibb

Phase 2

2 3

Tecentriq

Roche

Phase 2

2 4

Opdivo

Bristol-Myers Squibb

Phase 2

1 5

Farxiga

AstraZeneca

Phase 2

1 6

Beyfortus

BeiGene

Phase 2

1 7

Zofran

Novartis

Phase 2

1 8

Imfinzi

AstraZeneca

Phase 2

1 9

Nitrostat

VViatris Specialty LLC

Phase 2

1 10

Actemra

CCelltrion

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 2Recruiting

Hepatocellular Carcinoma (HCC)

NCT07463248

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma (HCC)1 trial

Personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy (PULSAR) Combined With Fecal Microbiota Transplantation (FMT) for Reversing Resistance to First-Line Targeted-Immunotherapy in Advanced HCC: A Clinical Application Study

Recruiting·WWang Xin·Phase 2·NCT07463248·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tislelizumab Combined With TKI. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tislelizumab Combined With TKI compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tislelizumab Combined With TKI. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Wang Xin company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: WWang Xin

Tislelizumab Combined With TKI

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Hepatocellular Carcinoma (HCC)1 trial

References

Drug Info

Quick Facts

Related News